Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling
Laura Cavalleri, Emilio Merlo Pich, Mark J. Millan, et al.
Molecular Psychiatry (2017) Vol. 23, Iss. 4, pp. 812-823
Open Access | Times Cited: 131

Showing 1-25 of 131 citing articles:

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Panos Zanos, Ruin Moaddel, Patrick J. Morris, et al.
Pharmacological Reviews (2018) Vol. 70, Iss. 3, pp. 621-660
Open Access | Times Cited: 959
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Nolan Williams, Boris D. Heifets, Christine Blasey, et al.
American Journal of Psychiatry (2018) Vol. 175, Iss. 12, pp. 1205-1215
Open Access | Times Cited: 420
Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective
Kenji Hashimoto
Psychiatry and Clinical Neurosciences (2019) Vol. 73, Iss. 10, pp. 613-627
Open Access | Times Cited: 288
Molecular pathways of major depressive disorder converge on the synapse
Gabriel R. Fries, Valeria Saldana, Johannes Finnstein, et al.
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 284-297
Open Access | Times Cited: 249
Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences
Stefano Aringhieri, Marco Carli, Shivakumar Kolachalam, et al.
Pharmacology & Therapeutics (2018) Vol. 192, pp. 20-41
Closed Access | Times Cited: 177
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Lily R. Aleksandrova, Anthony G. Phillips
Trends in Pharmacological Sciences (2021) Vol. 42, Iss. 11, pp. 929-942
Closed Access | Times Cited: 172
Mechanisms of ketamine and its metabolites as antidepressants
Evan Hess, Lace M. Riggs, Michael Michaelides, et al.
Biochemical Pharmacology (2021) Vol. 197, pp. 114892-114892
Open Access | Times Cited: 119
The role of brain derived neurotrophic factor in central nervous system
Yiyi Li, Fang Li, Dongdong Qin, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 84
PI3K-AKT/mTOR Signaling in Psychiatric Disorders: A Valuable Target to Stimulate or Suppress?
Yan Chen, Wei Guan, Meilan Wang, et al.
The International Journal of Neuropsychopharmacology (2024) Vol. 27, Iss. 2
Open Access | Times Cited: 19
Neuroplasticity and Psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models
Claudio Agnorelli, Meg J. Spriggs, Kate Godfrey, et al.
Neuroscience & Biobehavioral Reviews (2025) Vol. 172, pp. 106132-106132
Open Access | Times Cited: 2
Convergent Mechanisms Underlying Rapid Antidepressant Action
Panos Zanos, Scott M. Thompson, Ronald S. Duman, et al.
CNS Drugs (2018) Vol. 32, Iss. 3, pp. 197-227
Open Access | Times Cited: 156
Antidepressant-relevant concentrations of the ketamine metabolite (2 R ,6 R )-hydroxynorketamine do not block NMDA receptor function
Eric W. Lumsden, Timothy A. Troppoli, Scott J. Myers, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 11, pp. 5160-5169
Open Access | Times Cited: 135
( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions
Panos Zanos, Jaclyn N. Highland, Brent W. Stewart, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 13, pp. 6441-6450
Open Access | Times Cited: 128
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Todd D. Gould, Carlos A. Zarate, Scott M. Thompson
The Annual Review of Pharmacology and Toxicology (2018) Vol. 59, Iss. 1, pp. 213-236
Open Access | Times Cited: 117
Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
Bashkim Kadriu, Maximillian Greenwald, Ioline D. Henter, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 24, Iss. 1, pp. 8-21
Open Access | Times Cited: 81
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications
Jaclyn N. Highland, Panos Zanos, Lace M. Riggs, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 2, pp. 763-791
Open Access | Times Cited: 75
Ketamine and the Future of Rapid-Acting Antidepressants
Lace M. Riggs, Todd D. Gould
Annual Review of Clinical Psychology (2021) Vol. 17, Iss. 1, pp. 207-231
Open Access | Times Cited: 64
(R)‐Ketamine exerts antidepressant actions partly via conversion to (2R,6R)‐hydroxynorketamine, while causing adverse effects at sub‐anaesthetic doses
Panos Zanos, Jaclyn N. Highland, Xin Liu, et al.
British Journal of Pharmacology (2019) Vol. 176, Iss. 14, pp. 2573-2592
Open Access | Times Cited: 76
Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression
Cristan Farmer, Jessica R. Gilbert, Ruin Moaddel, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 8, pp. 1398-1404
Open Access | Times Cited: 69
The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity
Melody J.Y. Kang, Emily R. Hawken, Gustavo Vázquez
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 32
Recommendations, guidelines, and best practice for the use of human induced pluripotent stem cells for neuropharmacological studies of neuropsychiatric disorders
Lucia Dutan Polit, Ilse Eidhof, Rhiannon V. McNeill, et al.
Neuroscience Applied (2023) Vol. 2, pp. 101125-101125
Open Access | Times Cited: 18
Natural product Kaji-ichigoside F1 exhibits rapid antidepression via activating the AMPA–BDNF–mTOR pathway and inhibiting the NMDAR–CaMKIIα pathway
Faju Chen, Liangqun Li, Maoyang Huang, et al.
Phytomedicine (2024) Vol. 126, pp. 155452-155452
Closed Access | Times Cited: 7
A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)‐Hydroxynorketamine in Healthy Volunteers
Shruti M. Raja, Jeffrey T. Guptill, Michelle Mack, et al.
Clinical Pharmacology & Therapeutics (2024)
Open Access | Times Cited: 7
Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine
Jaclyn N. Highland, Patrick J. Morris, Panos Zanos, et al.
Journal of Psychopharmacology (2018) Vol. 33, Iss. 1, pp. 12-24
Open Access | Times Cited: 51
Changes in Hippocampal Plasticity in Depression and Therapeutic Approaches Influencing These Changes
Wenbo Xu, Xiaoxiao Yao, Fangyi Zhao, et al.
Neural Plasticity (2020) Vol. 2020, pp. 1-16
Open Access | Times Cited: 50
Page 1 - Next Page

Scroll to top